Astrazeneca to present 43 abstracts at US diabetes conference

11th Jun 2014 07:47

Drug giant AstraZeneca on Wednesday revealed that the American Diabetes Association (ADA) in San Francisco has accepted 43 diabetes research and development studies.The FTSE 100 group, which has been facing a takeover bid from US rival Pfizer, will present clinical data from a number of analyses, including that into the investigational combination of saxagliptin and dapagliflozin for adult patients with type 2 diabetes.Chief Executive Pascal Soriot said: "The robust scientific data to be presented at ADA further strengthen our broad innovative portfolio that spans the entire spectrum of non-insulin anti-diabetic treatments. "Our continued focus on advancing scientific knowledge reinforces our long-term commitment to diabetes, a core strategic area for us and an important platform for returning AstraZeneca to growth." The data being presented by the company also includes trials evaluating its medicines in patients with significant co-morbidities and in combination with other anti-diabetic agents, as part of its efforts to develop treatments for patients at different stages of the disease. Shares had moved 0.16% higher to 4,355p by 08:27 on Wednesday. NR